IVA Articles, Inventiva S.A. - From 02/16/24

On Friday, in its fourth-quarter 2023 earnings release, Inventiva SA (NASDAQ:IVA) said it has voluntarily paused screening and randomizat...

Shares of The Trade Desk, Inc. (NASDAQ: TTD) shares rose sharply in today’s pre-market trading after the company reported mixed fourth-quart...

U.S. stock futures were mixed this morning, with the Nasdaq futures trading higher by around 100 points on Friday. Shares of Yelp Inc. (NYSE: YEL...

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-t...

       Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stag...

Inventiva intends to use the proceeds to fund part of its ongoing pivotal NATiV3 Phase III clinical trial evaluating lanifibranor in patients wit...

The first patient was randomized in China in the NATiV3 Phase III clinical trial, triggering a milestone payment of $3 million from CTTQ to Inven...

The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety data The safet...

Cash and cash equivalents at €43.8 million, short-term deposits at €0.03 million2, and long-term deposit at €5.0 million3 as of September 3...

The phase II study led by Dr. Kenneth Cusi evaluating lanifibranor in patients with T2D and MASLD was selected as late breaker. Two additional sc...